fluoxetine

(redirected from Symbyax)
Also found in: Dictionary, Thesaurus.

fluoxetine

 [floo-ok´sĕ-tēn]
a selective serotonin reuptake inhibitor administered orally as the hydrochloride salt as an antidepressant and in the treatment of obsessive-compulsive disorder, bulimia nervosa, and premenstrual dysphoric disorder.

fluoxetine

(flo͞o′ŏk′sĭ-tēn′)
n.
A drug of the SSRI class, C17H18F3NO, used in its hydrochloride form to treat depression, obsessive-compulsive disorder, panic disorder, premenstrual dysphoric disorder, and certain eating disorders.

fluoxetine

Prozac® Neuropharmacology A selective inhibitor of serotonin reuptake used for clinical depression and other psychiatric disorders Adverse effects Anxiety, nervousness, tremor, insomnia, diarrhea, nausea, anorexia, undesired weight loss, sexual dysfunction Contraindications MAOI therapy. See Serotonin-selective reuptake inhibitor.

fluoxetine

An antidepressant drug that acts by prolonging the action of the NEUROTRANSMITTER 5-hydroxytryptamine (5HT or serotonin). It is a SELECTIVE SEROTONIN RE-UPTAKE INHIBITOR. It is taken by mouth. This drug is currently being taken by some 10 million people, mainly in the USA, and is said to be the most popular psychoactive drug in the history of pharmacology. It has attracted a great deal of attention as a ‘mood brightener’ and enhancer of optimism. It is claimed to be capable of altering personality for the better. Possible side effects include nausea, vomiting, diarrhoea, insomnia, anxiety, outbursts of violence, fever, skin rash and convulsions. This drug can interact dangerously, even fatally, with MAOIs. A brand name is Prozac.

Fluoxetine

Prozac; the first SSRI; marketed as Sarafem for treating PMDD.
References in periodicals archive ?
Few physicians choose Symbyax because of side effects--the weight gain and metabolic effects, he added.
Symbyax is fine to use for 6-8 weeks, but no one knows if long-term use might destabilize patient mood.
Symbyax is marketed by Lilly USA and is approved for the acute treatment of treatment-resistant depression and bipolar I depression in adults.
The only approved drug treatment for bipolar depression is a combination of olanzapine and fluoxetine marketed as Symbyax.
The regulatory clearance of Eli Lilly and Co.'s Symbyax for TRD marks a milestone for the pharmaceutical company.
The letter also pointed out a change in the labeling of olanzapine (as well as Symbyax, an olanzapine and fluoxetine combination drug approved in December for the treatment of bipolar depression) indicating the addition of a warning that cerebrovascular adverse events, including fatalities, were reported in patients in trials of olanzapine use in elderly patients with dementia.
The combination product was approved by the Food and Drug Administration in December and is marketed under the brand name of Symbyax, by Eli Lilly & Co., its manufacturer.
Such major products in established lines as Gemzar, an anticancer drug, and Humalog, an injectable insulin, should perform well, and sales increases are also expected from such newer products as Forteo for severe osteoporosis; Alimta, an oncology agent; Symbyax for bipolar depression; and Cymbalta, an antidepressant.
Nausea and diarrhea are more common with Symbyax therapy.
Lurasidone * Latuda Mirtazapine * Remeron Moclobemide * Amira, Aurorix, Clobemix, Depnil, Manerix Modafinil * Provigil Olanzapine/fluoxetine * Symbyax Paroxetine * Paxil Phenelzine * Nardil Pramipexole * Mirapex Quetiapine * Seroquel Riluzole * Rilutek Sertraline * Zoloft Vortioxetine * Brintellix
It will be marketed as Symbyax by Eli Lilly & Co., the manufacturer of both drugs.